Neuroendocrine tumours (NETs) is a term for rare malignancies that arise in neuroendocrine cells anywhere in the body. The most common sites are the gastrointestinal tract, pancreas and lungs. Between 1995 and 2018 there was a 371% rise in cases per 100,0001. Although reasons for this increase in incidence are unclear, developing effective therapies is a priority as treatment options remain limited.
Tumour characteristics of NETs determine the available therapeutic options2. These characteristics vary among the different subtypes, which arise from cells of the neuroendocrine system. A modern therapeutic development for NETs that express receptors for somatostatin is the peptide receptor radionuclide therapy 177Lu-DOTATATE3. 177Lu is a beta-emitting radioisotope, whilst DOTATATE refers to the carrier molecule, which is a synthetic somatostatin receptor agonist that binds to the somatostatin peptide surface receptors on the tumour. The emission of...
Sign in to your account
Log in
This content is available to registered users only. Please sign in to continue.
If you are not yet registered, please create your account on www.sor.org and verify your membership status. Once your account has been set up, return here and sign in to access the content.
Set up your account